Dose comparison of conivaptan (Vaprisol(®)) in patients with euvolemic or hypervolemic hyponatremia – efficacy, safety, and pharmacokinetics

PURPOSE: This study aimed to evaluate the efficacy, safety, and pharmacokinetics of 20 and 40 mg/day conivaptan (Vaprisol(®)) in patients with hypervolemic or euvolemic hyponatremia. METHODS: Hyponatremic patients – serum sodium (sNa) ≤130 mEq/L – received either 20 or 40 mg/day of conivaptan for 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, Biff F, Rock, Amy D, Woodward, Emily J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723016/
https://www.ncbi.nlm.nih.gov/pubmed/26848258
http://dx.doi.org/10.2147/DDDT.S95326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723016/
https://www.ncbi.nlm.nih.gov/pubmed/26848258
http://dx.doi.org/10.2147/DDDT.S95326

Ejemplares similares